Page 42 - Read Online

Page 14 of 15 D'Souza et al. J Cancer Metastasis Treat 2022;8:28 https://dx.doi.org/10.20517/2394-4722.2022.51

65. Alvarez-Vallina L, Russell SJ. Efficient discrimination between different densities of target antigen by tetracycline-regulatable T
bodies. Hum Gene Ther 1999;10:559-63. DOI PubMed
66. Watanabe K, Terakura S, Martens AC, et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen
receptor-modified effector CD8+ T cells. J Immunol 2015;194:911-20. DOI PubMed
67. Chmielewski M, Hombach AA, Abken H. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-
redirected T-cell attack. Gene Ther 2011;18:62-72. DOI PubMed
68. Frigault MJ, Lee J, Basil MC, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of
T cells. Cancer Immunol Res 2015;3:356-67. DOI PubMed PMC
69. Viganò S, Utzschneider DT, Perreau M, Pantaleo G, Zehn D, Harari A. Functional avidity: a measure to predict the efficacy of
effector T cells? Clin Dev Immunol 2012;2012:153863. DOI PubMed PMC
70. Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro
and in vivo antitumor efficacy. J Immunol 1999;162:989-94. PubMed
71. Walker AJ, Majzner RG, Zhang L, et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor
targeting anaplastic lymphoma kinase. Mol Ther 2017;25:2189-201. DOI PubMed PMC
72. Arcangeli S, Rotiroti MC, Bardelli M, et al. Balance of Anti-CD123 chimeric antigen receptor binding affinity and density for the
targeting of acute myeloid leukemia. Mol Ther 2017;25:1933-45. DOI PubMed PMC
73. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the
administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51. DOI PubMed
PMC
74. Liu X, Jiang S, Fang C, et al. Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index
against tumors in mice. Cancer Res 2015;75:3596-607. DOI PubMed PMC
75. Drent E, Themeli M, Poels R, et al. A rational strategy for reducing On-Target Off-Tumor effects of CD38-chimeric antigen receptors
by affinity optimization. Mol Ther 2017;25:1946-58. DOI PubMed PMC
76. O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen
loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017;9:eaaa0984. DOI PubMed PMC
77. Rafiq S, Brentjens RJ. Tumors evading CARs-the chase is on. Nat Med 2018;24:1492-3. DOI PubMed
78. Larson RC, Kann MC, Bailey SR, et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature
2022;604:563-70. DOI
79. Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin
Invest 2016;126:3036-52. DOI
80. Dao T, Pankov D, Scott A, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat
Biotechnol 2015;33:1079-86. DOI PubMed PMC
81. Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with
malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab. Cancer Discov 2021;11:2748-63. DOI PubMed
PMC
82. Brossart P. The Role of antigen spreading in the efficacy of immunotherapies. Clin Cancer Res 2020;26:4442-7. DOI PubMed
83. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor
activity in solid malignancies. Cancer Immunol Res 2014;2:112-20. DOI PubMed PMC
84. Klampatsa A, Leibowitz MS, Sun J, Liousia M, Arguiri E, Albelda SM. Analysis and augmentation of the immunologic bystander
effects of car T cell therapy in a syngeneic mouse cancer model. Mol Ther Oncolytics 2020;18:360-71. DOI PubMed PMC
85. Choe JH, Watchmaker PB, Simic MS, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and
persistence in treating glioblastoma. Sci Transl Med 2021;13:eabe7378. DOI PubMed PMC
86. Anurathapan U, Chan RC, Hindi HF, et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther
2014;22:623-33. DOI PubMed PMC
87. Song DG, Ye Q, Poussin M, Chacon JA, Figini M, Powell DJ. Effective adoptive immunotherapy of triple-negative breast cancer by
folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol 2016;9:56. DOI
PubMed PMC
88. Smith TT, Moffett HF, Stephan SB, et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate
heterogeneous tumors. J Clin Invest 2017;127:2176-91. DOI PubMed PMC
89. Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell
motility and invasion via MMP-7 activation. Sci Rep 2013;3:1870. DOI PubMed PMC
90. Zhang L, Yu Z, Muranski P, et al. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly
enhances tumor treatment efficacy. Gene Ther 2013;20:575-80. DOI PubMed PMC
91. Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-
mediated inhibition. J Clin Invest 2016;126:3130-44. DOI PubMed PMC
92. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target
immunotherapy responses. Sci Transl Med 2013;5:215ra172. DOI PubMed PMC
93. Rodgers DT, Mazagova M, Hampton EN, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Proc Natl Acad Sci USA 2016;113:E459-68. DOI PubMed PMC